ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för netupitant. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

18 träffar

Bibliografisk träff 2015-02-14

Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.

Darmani NA, Zhong W, Chebolu S, Mercadante F.

Pharmacol Biochem Behav · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pbb.2015.02.010

Bibliografisk träff 2014-12-17

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).

Navari RM.

Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s76158

Bibliografisk träff 2014-12-01

Netupitant-palonosetron combination approved by FDA.

Thompson CA.

Am J Health Syst Pharm · news · DOI 10.2146/news140079

Bibliografisk träff 2014-10-31

Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.

Lorusso V, Karthaus M, Aapro M.

Future Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.2217/fon.14.260

Bibliografisk träff 2014-09-16

Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.

Schwartzberg L.

Expert Rev Pharmacoecon Outcomes Res · research support, non-u.s. gov't; review; journal article · DOI 10.1586/14737167.2014.957683

Bibliografisk träff 2014-07-30

Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain.

Greenwood-Van Meerveld B, Mohammadi E, Tyler K, Pietra C, Bee LA, Dickenson A.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.114.216028

Bibliografisk träff 2014-07-29

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial.

Spinelli T, Moresino C, Baumann S, Timmer W, Schultz A.

Springerplus · research-article; journal article · DOI 10.1186/2193-1801-3-389

Bibliografisk träff 2014-06-27

Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.

Thomas AG, Stathis M, Rojas C, Slusher BS.

Exp Brain Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00221-014-4017-7

Bibliografisk träff 2014-06-18

Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?

Andrews PLR.

Ann Oncol · editorial · DOI 10.1093/annonc/mdu190

Bibliografisk träff 2014-03-14

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K.

Ann Oncol · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1093/annonc/mdu096

Bibliografisk träff 2014-03-07

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ.

Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1093/annonc/mdu110

Bibliografisk träff 2014-03-05

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S.

Ann Oncol · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1093/annonc/mdu101

Bibliografisk träff 2014-01-28

Role of neurokinin 1 receptors in dextran sulfate-induced colitis: studies with gene-deleted mice and the selective receptor antagonist netupitant.

Szitter I, Pintér E, Perkecz A, Kemény A, Kun J, Kereskai L, Pietra C, Quinn JP, Zimmer A, Berger A, Paige CJ, Helyes Z.

Inflamm Res · research support, non-u.s. gov't; journal article · DOI 10.1007/s00011-014-0712-x

Bibliografisk träff 2013-11-08

Netupitant PET imaging and ADME studies in humans.

Spinelli T, Calcagnile S, Giuliano C, Rossi G, Lanzarotti C, Mair S, Stevens L, Nisbet I.

J Clin Pharmacol · research-article; randomized controlled trial; journal article · DOI 10.1002/jcph.198

Bibliografisk träff 2013-06-14

Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder.

Haab F, Braticevici B, Krivoborodov G, Palmas M, Zufferli Russo M, Pietra C.

Neurourol Urodyn · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1002/nau.22406

Bibliografisk träff 2013-06-11

Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.

Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W.

Support Care Cancer · research support, non-u.s. gov't; journal article · DOI 10.1007/s00520-013-1857-9

Bibliografisk träff 2013-06-01

Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone.

Lanzarotti C, Rossi G.

Support Care Cancer · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s00520-013-1855-y

Bibliografisk träff 2012-06-23

In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.

Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo' G.

Peptides · research support, non-u.s. gov't; journal article · DOI 10.1016/j.peptides.2012.06.010